Targeting Fibroblast Activation Protein for Precision Medicine
Accounts of Chemical Research · 18.08.2026 · 59 (16) · 2615-2634
DOI: 10.1021/acs.accounts.6c00139 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Accounts of Chemical Research, online erschienen am 04.08.2026. Verfasst von Jie Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology and Shandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Shandong First…. Hauptthemen laut MEDLINE: Gelatinases, Precision Medicine, Membrane Proteins, Serine Endopeptidases. Die Arbeit nennt 123 Literaturangaben. Gefördert von: National Medical Research Council, National University of Singapore, National Research Foundation Singapore.
Abstract (Originalsprache)
Conspectus The advancement of precision medicine depends critically on well-defined molecular targets. Pathologically activated fibroblasts drive disease progression in cancer, fibrosis and chronic inflammation through sustained inflammation, extracellular matrix remodeling and pathological microenvironment formation. Among available markers, fibroblast activation protein (FAP) stands out due to its selective overexpression in diseased tissues versus minimal expression in healthy organs. This unique profile makes FAP a promising target for molecular imaging and targeted therapy, enabling precision theranostics across both oncological and nononcological diseases. FAP-targeted theranostics originated from the lead compound PT-100, which established the core pharmacophore. Subsequent key advance was the replacement of the boronic acid warhead with a cyano group, along with the introduction of fluorine and quinoline moieties, yielding the UAMC-1110 scaffold. This scaffold exhibits improved bioactivity and favorable pharmacokinetics. Systematic modification of the quinoline side chain and conjugation with chelators have allowed efficient radiolabeling, positioning radiolabeled FAP inhibitors as promising tools for precision theranostics. However, continued optimization of UAMC-1110-derived probes to enhance their stability, affinity, tumor retention, and cellular uptake, together with integration into advanced strategies such as nanomedicine, remains essential not only for refining FAP-targeted precision medicine but also for expanding its applications beyond oncology to nononcological diseases. Unlike previous reviews, this Account organizes the field around a unified chemical design language, following a “rational design-pharmacokinetics-translational validation” paradigm. After delineating the core biological functions of FAP-expressing fibroblasts in disease pathogenesis, we systematically examine the rapid advancement of radionuclide-labeled FAPIs, including optimization of linkers, chelators, and albumin-binding moieties, along with multimerization strategies, which significantly enhanced the pharmacokinetic profiles. Key innovations in the field include three strategic approaches. First, the albumin-binding therapeutic agent [177Lu]Lu-EB-FAPI achieves prolonged tumor retention and promising efficacy. Second, multimerization strategies have yielded bivalent and tetrameric FAPI constructs, which exhibit superior tumor accumulation. Third, heterodimeric probes such as [68Ga]Ga-FAPI-RGD and [68Ga]Ga-FAPI-LM3 enable dual targeting of FAP along with integrin αvβ3 or somatostatin receptor SSTR2, thereby addressing tumor heterogeneity and enhancing lesion detectability. Subsequently, the application scope of FAPI-based imaging has been expanded from oncology to nononcological diseases. The value of this technique in visualizing dynamic remodeling processes across key pathologic conditions has been established, offering quantitative assessment beyond the reach of standard modalities. Furthermore, we review recent advances in diverse FAP-targeted therapeutic strategies, including nanomaterials, CAR-T cells, and vaccines, and offer a forward-looking perspective on both the potential and the ongoing challenges of FAP as a cross-disease precision theranostic platform.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology and Shandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan250…
- Center for Nuclear Medicine and Molecular Imaging (CNMMI), Shandong Cancer Hospital and Institute, Jinan250117, China.
- Department of Diagnostic Radiology, Yong Loo Lin School of Medicine and College of Design and Engineering, National University of Singapore, Singapore119074, Singapore.
- Theranostics Centre of Excellence (TCE), Yong Loo Lin School of Medicine, National University of Singapore, Singapore138667, Singapore.
- Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore117599, Singapore.
ORCID-Profile: Xiaoyuan Chen, Jingjing Zhang
Förderung
- National Medical Research Council
- National University of Singapore
- National Research Foundation Singapore
- Ministry of Education - Singapore
- China Postdoctoral Science Foundation
- Natural Science Foundation of Shandong Province
- Taishan Scholar Project of Shandong Province
- National Natural Science Foundation of China (NSFC)
Zitieren
APA
Liu, J., Zhao, X., Liu, P., Yu, J., Chen, X., & Zhang, J. (2026). Targeting Fibroblast Activation Protein for Precision Medicine. Accounts of Chemical Research, 59(16), 2615-2634. https://doi.org/10.1021/acs.accounts.6c00139
Vancouver
Liu J, Zhao X, Liu P, Yu J, Chen X, Zhang J. Targeting Fibroblast Activation Protein for Precision Medicine. Accounts of Chemical Research. 2026;59(16):2615-2634. doi:10.1021/acs.accounts.6c00139
BibTeX
@article{Liu2026,
author = {Liu, Jie and Zhao, Xinzhi and Liu, Peifei and Yu, Jinming and Chen, Xiaoyuan and Zhang, Jingjing},
title = {Targeting Fibroblast Activation Protein for Precision Medicine},
journal = {Accounts of Chemical Research},
year = {2026},
volume = {59},
number = {16},
pages = {2615--2634},
doi = {10.1021/acs.accounts.6c00139}
}
EUVIMED